Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

748
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
748
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

640
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
640
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

578
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
578
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

497
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
497
Clinical Trials01:16

Clinical Trials

10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 1.

Korean circulation journal·2026
Same author

Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 2.

Korean circulation journal·2026
Same author

Contemporary Clinical Practices in Korean Patients With Coronary Chronic Total Occlusion: Results From the K-CTO Nationwide Retrospective Registry.

Korean circulation journal·2026
Same author

Effect of Low-Dose Rivaroxaban Plus Aspirin on 18F-FDG PET/CT-Detectable Carotid Plaque Inflammation: A Randomised Trial.

European heart journal. Cardiovascular Imaging·2026
Same author

Implementation of decentralized clinical trials in Korea from a resource-based perspective.

Translational and clinical pharmacology·2026
Same author

Prediction of Clinical Outcomes Based on Phenotypic Grouping Using Left Ventricular and Left Atrial Strains in Patients with HFpEF.

European heart journal. Cardiovascular Imaging·2026

Related Experiment Video

Updated: Feb 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.

Jeong Cheon Ahn1, Cheol Whan Lee2, Jong Hwa Ahn3

  • 1Department of Cardiology, Korea University Ansan Hospital (J.C.A.).

Hypertension (Dallas, Tex. : 1979)
|February 20, 2026
PubMed
Summary

A low-dose triple pill combining telmisartan, amlodipine, and chlorthalidone effectively lowers blood pressure compared to standard telmisartan monotherapy. This combination therapy is safe and well-tolerated, offering a superior treatment option for essential hypertension.

Keywords:
amlodipineantihypertensive agentsblood pressurechlorthalidonehypertensiontelmisartan

Related Experiment Videos

Last Updated: Feb 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Limited studies compare low-dose triple single-pill combinations to standard-dose monotherapies for hypertension.
  • Essential hypertension management often involves complex medication regimens.
  • Single-pill combinations aim to improve adherence and efficacy.

Purpose of the Study:

  • To evaluate the efficacy and safety of a low-dose triple single-pill combination (telmisartan/amlodipine/chlorthalidone) versus standard-dose telmisartan monotherapy.
  • To determine if the combination therapy is non-inferior and superior in reducing blood pressure.
  • To assess the safety profile of the combination therapy in patients with essential hypertension.

Main Methods:

  • Phase III, randomized, double-blind trial involving 314 patients with essential hypertension.
  • Randomization to either telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg or telmisartan 40 mg for 8 weeks post-placebo run-in.
  • Primary endpoint: change in mean sitting systolic blood pressure; secondary endpoints included diastolic BP, normalization rates, and response rates.

Main Results:

  • The combination therapy achieved statistically significant reductions in systolic blood pressure, demonstrating non-inferiority and superiority over monotherapy (LS mean difference: -3.8 to -4.0 mmHg).
  • Improved outcomes were observed for diastolic blood pressure, BP normalization rates, and response rates at weeks 4 and 8.
  • Consistent efficacy was noted across various patient subgroups, with comparable safety and no serious drug-related adverse events.

Conclusions:

  • Low-dose triple single-pill combination therapy offers superior blood pressure-lowering efficacy compared to standard-dose telmisartan monotherapy.
  • The combination therapy is well-tolerated and demonstrates a comparable safety profile to monotherapy.
  • This regimen represents a promising advancement in managing essential hypertension.